Home › Crohn's Disease › Maryland
Crohn's Disease clinical trials in Maryland
15 studies for Crohn's Disease are looking for participants at sites in Maryland.
Cities in Maryland
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 85 · All sexes · Updated Oct 2, 2026 · NCT07619547A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Walter Reed National Military Medical Center ( Site 5006), Bethesda
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Oct 2, 2026 · NCT06430801A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Capital Digestive Care, Chevy Chase
- Woodholme Gastroenterology, Glen Burnie
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 30, 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Metropolitan Gastroenterology Group - Chevy Chase /ID# 265877, Chevy Chase
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Woodholme Gastroenterology Associates, Glen Burnie
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07499232A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- Chevy Chase Clinical Research, Chevy Chase
- Woodholme Gastroenterology Associates, Glen Burnie
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- Woodholme Gastroenterology Associates, Glen Burnie
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Capital Digestive Care - Chevy Chase, Chevy Chase
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- National Cancer Institute Developmental Therapeutics Clinic, Bethesda
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Mercy Medical Center, Baltimore-Site Number: 8400117, Baltimore
- Mid-Atlantic GI Research, LLC-Site Number: 8400106, Laurel
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Aug 27, 2026 · NCT03167437Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Mercy Medical Center, Baltimore
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07237516Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- The Johns Hopkins Children's Medical Center, Baltimore
RecruitingPhase 4
Ages 6 to 17 · All sexes · Updated May 27, 2026 · NCT05781152A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- Woodholme Gastroenterology Associates, Glen Burnie
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated May 22, 2026 · NCT06764615A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Johns Hopkins University, Baltimore
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated May 5, 2026 · NCT04779320From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.